140 related articles for article (PubMed ID: 31950021)
41. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
42. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
43. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
Oh HN; Lee MH; Kim E; Kwak AW; Seo JH; Yoon G; Cho SS; Choi JS; Lee SM; Seo KS; Chae JI; Shim JH
Phytother Res; 2020 Feb; 34(2):388-400. PubMed ID: 31698509
[TBL] [Abstract][Full Text] [Related]
44. Delivery of gefitinib in synergism with thymoquinone
Upadhyay P; Ghosh A; Basu A; Pranati PA; Gupta P; Das S; Sarker S; Bhattacharjee M; Bhattacharya S; Ghosh S; Chattopadhyay S; Adhikary A
Biomater Sci; 2021 Dec; 9(24):8285-8312. PubMed ID: 34766965
[TBL] [Abstract][Full Text] [Related]
45. Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.
Yeung YT; Yin S; Lu B; Fan S; Yang R; Bai R; Zhang C; Bode AM; Liu K; Dong Z
EBioMedicine; 2018 Feb; 28():51-61. PubMed ID: 29398601
[TBL] [Abstract][Full Text] [Related]
46. Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells.
Tong CWS; Wu MMX; Yan VW; Cho WCS; To KKW
Cancer Treat Res Commun; 2020; 25():100229. PubMed ID: 33152554
[TBL] [Abstract][Full Text] [Related]
47. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
[TBL] [Abstract][Full Text] [Related]
48. An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells.
Si Y; Pei X; Wang X; Han Q; Xu C; Zhang B
Protein Pept Lett; 2021; 28(11):1290-1297. PubMed ID: 34602035
[TBL] [Abstract][Full Text] [Related]
49. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
50. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zucali PA; Ruiz MG; Giovannetti E; Destro A; Varella-Garcia M; Floor K; Ceresoli GL; Rodriguez JA; Garassino I; Comoglio P; Roncalli M; Santoro A; Giaccone G
Ann Oncol; 2008 Sep; 19(9):1605-12. PubMed ID: 18467317
[TBL] [Abstract][Full Text] [Related]
51. Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.
Wang TH; Wu CC; Huang KY; Leu YL; Yang SC; Chen CL; Chen CY
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396393
[TBL] [Abstract][Full Text] [Related]
52. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
53. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
54. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
55. Angiogenic activities are increased via upregulation of HIF-1α expression in gefitinib-resistant non-small cell lung carcinoma cells.
Cha JE; Bae WY; Choi JS; Lee SH; Jeong JW
Oncol Lett; 2021 Sep; 22(3):671. PubMed ID: 34345296
[TBL] [Abstract][Full Text] [Related]
56. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
57. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
58. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
59. Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Iwasa T; Yoshida T; Hatashita E; Yamada Y; Satoh T; Tamura K; Fukuoka M; Nakagawa K
Mol Cancer Ther; 2008 Mar; 7(3):599-606. PubMed ID: 18347146
[TBL] [Abstract][Full Text] [Related]
60. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]